M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue

Phase 2

Active, not recruiting

Conditions: Cancer Fatigue
Acute Myeloid Leukemia
Lymphoma
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Secondary Acute Myeloid Leukemia

Interventions: Behavioral: Cognitive Behavior Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2018-11-20

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT03747757

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery

Phase 2

Active, not recruiting

Conditions: Pancreatic Carcinoma

Interventions: Other: Best Practice
Drug: Quadratus Lumborum Block
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2018-11-19

Last Posted Date: 2023-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 136

Registration Number: NCT03745794

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
Metastatic Urothelial Carcinoma
MTAP Negative

Interventions: Drug: Avelumab
Drug: Pemetrexed

First Posted Date: 2018-11-16

Last Posted Date: 2025-01-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT03744793

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Phase 2

Active, not recruiting

Conditions: Locally Advanced Malignant Neoplasm
Delirium
Recurrent Malignant Neoplasm
Metastatic Malignant Neoplasm

Interventions: Drug: Haloperidol
Drug: Lorazepam
Other: Placebo
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2018-11-16

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT03743649

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
🇧🇷
Hosptial de Cancer de Barretos, Barretos, Sao Paulo, Brazil

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

Phase 3

Recruiting

Conditions: Malignant Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Radiosurgery

First Posted Date: 2018-11-15

Last Posted Date: 2025-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 180

Registration Number: NCT03741673

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

Phase 2

Terminated

Conditions: HNSCC

Interventions: Drug: Bimiralisib

First Posted Date: 2018-11-14

Last Posted Date: 2023-07-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT03740100

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
Recurrent Acute Myeloid Leukemia
Refractory Acute Leukemia

Interventions: Drug: Quizartinib
Drug: Venetoclax

First Posted Date: 2018-11-08

Last Posted Date: 2023-10-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT03735875

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

Not Applicable

Active, not recruiting

Conditions: Stage IIB Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Behavioral: Behavioral Intervention
Other: Educational Intervention
Other: Questionnaire Administration
Procedure: Support Group Therapy

First Posted Date: 2018-11-06

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT03731585

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Estrogen Receptor Positive
HER2/Neu Negative
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Recurrent Breast Carcinoma
Anatomic Stage IIIB Breast Cancer AJCC v8
Metastatic Malignant Solid Neoplasm

Interventions: Drug: MDM2/MDMX Inhibitor ALRN-6924
Drug: Paclitaxel

First Posted Date: 2018-10-31

Last Posted Date: 2025-04-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03725436

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Ibrutinib
Drug: Methotrexate
Biological: Rituximab
Drug: Venetoclax
Drug: Vincristine Sulfate

First Posted Date: 2018-10-18

Last Posted Date: 2025-05-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT03710772

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy